Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017

Mostrar otras versiones (1)

The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Byung-Wan, Kim, Jin Hwa, Ko, Seung-Hyun, Hur, Kyu Yeon, Kim, Nan-Hee, Rhee, Sang Youl, Kim, Hyun Jin, Moon, Min Kyong, Park, Seok-O, Choi, Kyung Mook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668405/
https://www.ncbi.nlm.nih.gov/pubmed/29057642
http://dx.doi.org/10.3904/kjim.2017.314
Descripción
Sumario:The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM.

Ejemplares similares